Education
About Us
Working with TipRanks
Follow Us
Novartis (GB:0QLR)
LSE:0QLR
Earnings Data
Report Date
Apr 29, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
1.79Last Year’s EPS
1.55Same Quarter Last Year
Based on 13 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Jan 31, 2025
|% Change Since: 2.75%
|Next Earnings Date:Apr 29, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted a strong performance in 2024 with significant growth across key brands and advancements in the pipeline. However, there are challenges anticipated in 2025 due to potential generic entries and ongoing patent litigations, particularly concerning Entresto.Company Guidance
In the call, Novartis provided detailed guidance for its financial and operational performance. For 2024, the company achieved 12% sales growth and a 22% increase in core operating income, with margins reaching 38.7%. Key brands demonstrated strong growth, with Entresto achieving $7.8 billion in sales, up 31%, and Cosentyx reaching over $6 billion, growing 25%. The company exceeded its full-year guidance and is confident in continued growth in 2025, projecting mid to high single-digit sales growth and high single to low double-digit core operating income growth. Novartis also outlined its strategy for maintaining a 5% plus sales growth trajectory through 2029, with an aim to achieve a 40% margin by 2027. The call highlighted significant pipeline progress, including advancements in priority brands and upcoming readouts for new therapies that are expected to drive long-term growth.Record-Breaking Performance in 2024
Novartis delivered one of the strongest performances in its history with Q4 sales growth of 16% and core operating income growth of 29% in constant currency. For the full year, sales grew 12% and core operating income grew 22%.
Significant Growth Across Priority Brands
Priority brands grew 38% in constant currencies, with Entresto sales up 31% to $7.8 billion, Cosentyx sales growing 25%, Kesimpta growing 49%, and Kisqali achieving a 49% increase in sales.
Pipeline Advancements and Approvals
Notable pipeline advancements include the approvals for Kisqali in early breast cancer and Fabhalta in two indications. The company also announced a promising acquisition in neuroscience with PTC518 for Huntington's disease.
Strong Financial Metrics and Shareholder Returns
Free cash flow reached a record high of $16.3 billion, growing 24%. Novartis proposed its 28th consecutive dividend increase and completed over 30 bolt-on deals to strengthen its pipeline.
---
GB:0QLR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GB:0QLR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Jan 31, 2025 | CHF90.44 | CHF93.27 | +3.13% |
| Oct 29, 2024 | CHF95.50 | CHF93.18 | -2.43% |
| Jul 18, 2024 | CHF94.38 | CHF92.47 | -2.02% |
| Apr 23, 2024 | CHF84.08 | CHF86.92 | +3.38% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Novartis (GB:0QLR) report earnings?
Novartis (GB:0QLR) is schdueled to report earning on Apr 29, 2025, TBA Not Confirmed.
What is Novartis (GB:0QLR) earnings time?
Novartis (GB:0QLR) earnings time is at Apr 29, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Novartis stock?
The P/E ratio of Novartis AG is N/A.
What is GB:0QLR EPS forecast?
GB:0QLR EPS forecast for the fiscal quarter 2025 (Q1) is 1.79.
---